Novo Nordisk holds analyst rating, JPMorgan reiterates Neutral on the shares

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-29, 09:09.

Novo Nordisk (DK0062498333) stays on JPMorgan’s Neutral list this morning. The US bank reiterates its rating and sets a 250 Danish kroner price target for the Copenhagen-listed pharma group, according to the dpa-AFX analyzer summary and Marketscreener data, with the shares part of the OMX Copenhagen 25 and Stoxx Europe 600 indices. dpa-AFX analyzer overview at FinanzNachrichten

What JPMorgan reiterates today

According to a note cited by dpa-AFX and relayed on FinanzNachrichten and Marketscreener, JPMorgan keeps Novo Nordisk at Neutral and confirms a 250 kroner price target for the shares. Marketscreener analyst summary on Novo Nordisk The update was reported around 08:13 local time, indicating that the bank does not see a need for a rating or target change despite the stock’s recent gains in the pharma and obesity treatment segment.

JPMorgan’s stance comes after Novo Nordisk’s sustained share price strength on the Copenhagen exchange, where the B shares trade at around 317.95 kroner as of the latest closing print on June 26, 2026, implying an 8.53 percent gain year-to-date according to Marketscreener. Marketscreener price and performance data The Neutral rating and 250 kroner target therefore sit below the current market level, signaling a cautious view on further upside at this stage.

How consensus on the stock looks

Beyond JPMorgan, Novo Nordisk remains a core holding in European healthcare indices such as Stoxx Europe 50 and Stoxx Europe 600, and features prominently in the OMX Copenhagen 25 benchmark, according to FinanzNachrichten’s company classification. FinanzNachrichten company and index overview Analyst coverage in aggregate continues to reflect a mix of Buy and Hold recommendations, with the JPMorgan Neutral stance representing the more cautious end of the spectrum.

On Marketscreener, Novo Nordisk’s B share is shown with a recent closing price of 317.95 kroner and a five-day performance of plus 0.73 percent, while the year-to-date gain of 8.53 percent illustrates solid momentum within the European large-cap pharma space. Marketscreener performance figures for Novo Nordisk B For retail investors tracking analyst targets, the 250 kroner level highlighted by JPMorgan stands as a reference point relative to these current market prices.

The products behind the stock

Novo Nordisk generates most of its revenue from diabetes and obesity therapies, including its widely known injectable semaglutide brands Ozempic for type 2 diabetes and Wegovy for obesity, alongside insulin products and other chronic disease treatments detailed on its Investor Relations site. Novo Nordisk product overview for investors

Where the shares trade today

As of 2026-06-26, 16:00 ET, Novo Nordisk’s ADR trades on the NYSE under the ticker NVO at 48.07 US dollars, with a market capitalization of around 161.68 billion dollars, according to TradingKey’s real-time market data. TradingKey quote and market cap for NVO

Disclaimer: This article provides factual information on the Novo Nordisk shares and does not contain investment advice or recommendations. Investors should form their own judgment and, where appropriate, consult a qualified financial advisor.